TEVA in 60 seconds
- TEVA is a CFD on Teva's NYSE American Depositary Shares. You take a long or short view in USD and you do not become a shareholder of record.
- Maximum leverage at LHFX is 1:20. A share around the $18 mark needs roughly $0.90 of margin at the cap, but a 5% adverse tick wipes out that margin.
- Round-trip cost on a TEVA CFD is the raw spread plus commission of $3 per side per standard lot ($6 round trip on 1.00 lot). Execution is STP/ECN on MetaTrader 5.
- Three forces dominate the tape: AUSTEDO revenue growth, quarterly opioid-settlement cash outflows, and the Humira and Stelara biosimilar launch curves.
- There is no dividend right now. Teva paused payouts in 2017 to repair the balance sheet after the Actavis Generics acquisition and has not restarted them as of late 2025.
What Teva Pharmaceutical actually does
Teva Pharmaceutical Industries was founded in Jerusalem in 1901 and now runs out of Tel Aviv, with manufacturing and distribution in roughly 60 countries. The catalogue holds more than 3,500 generic medicines, which is the largest such portfolio anywhere on the planet by SKU count and by revenue. In the US alone, roughly one in seven generic prescriptions filled at the pharmacy counter comes off a Teva production line, although the company does not advertise that fact to consumers.
The 2024 full-year revenue number was around $16.5 billion, roughly level with 2023 in reported dollars. That flat headline hides two opposite trends. The Generic Medicines segment, which makes up 53% of revenue, is shrinking modestly each year because of structural US price erosion. The Innovative Medicines segment, at 28% of revenue, is growing at a double-digit pace thanks almost entirely to AUSTEDO. The remaining 19% is a mix of biosimilars, active pharmaceutical ingredient sales to third-party drug makers, and over-the-counter consumer products.
Geographic split is worth pinning down. North America is 54% of revenue, Europe is 29%, and the International Markets segment (Latin America, Asia-Pacific, Africa, Middle East) is 17%. The Tel Aviv home market is a small share of revenue but matters enormously to local investors and the dual listing means Israeli geopolitical news regularly produces overnight TEVA gaps that traders in New York wake up to.
Three businesses inside one ticker
TEVA is best modelled as three different companies stapled together. Each has its own growth profile, its own gross margin range, and its own catalyst calendar.
| Generic Medicines | 53% of 2024 revenue | Off-patent versions of branded drugs sold mainly to retail pharmacy chains, wholesalers, and group purchasing organisations. Gross margin sits in the mid-40s. Volume grows slowly while average selling price slips 3 to 6% a year in the US. This segment is the cash cow that funds the rest. |
| Innovative Medicines | 28% of 2024 revenue | Branded specialty products with patent protection. AUSTEDO (deutetrabenazine) for tardive dyskinesia and Huntington chorea is the franchise leader. AJOVY (fremanezumab) for migraine prevention is the second pillar. Gross margin runs above 70%. The AUSTEDO XR sustained-release line grew above 30% in 2024 and pushed total franchise sales past $1.6 billion. |
| Biosimilars, API, OTC | 19% of 2024 revenue | SIMLANDI (a Humira biosimilar) launched into the US market in 2024. A Stelara biosimilar and a Prolia biosimilar are next in line. Active pharmaceutical ingredient sales to other generic makers and over-the-counter products round out the bucket. Gross margins vary widely across the items, from low-30s on commodity API to mid-50s on biosimilars. |
Investors who treat TEVA as a single business will mis-read every quarterly report. The Generic Medicines line can shrink 4% while AUSTEDO grows 30% and the overall print still looks flat. That mix shift is the whole investment thesis.
What moves the TEVA share price
The AUSTEDO ramp toward $2.5 billion
Management has publicly guided the AUSTEDO franchise to $2.5 billion of annual revenue by 2027, starting from $1.6 billion in 2024. Every quarterly earnings call is parsed for the franchise growth rate. A print below 25% year-on-year tends to compress the multiple. A print above 30% tends to extend it. Consensus EPS revisions for the following four quarters move within hours of the AUSTEDO line being read out.
The $4.25 billion opioid payout schedule
Teva settled with the coalition of US states for $4.25 billion in cash and donated product, paid out over 13 years. Each quarterly tranche is a hard claim on free cash flow that would otherwise pay down debt or fund the pipeline. Any announcement of an accelerated payment, an additional state opting in, or a new tribal-level claim is treated by the tape as incremental bad news.
The US generic-pricing curve
Annual price erosion of 3 to 6% on US generics has been the baseline assumption for years. A single procurement decision by Walmart, CVS, Express Scripts, or a hospital group purchasing organisation can move the curve by 100 basis points in either direction. Teva's North American Generic Medicines line is the most exposed in the industry to that number.
Biosimilar launch trajectories
SIMLANDI is the live Humira biosimilar fight. Sandoz, Amgen, Boehringer, and several others are chasing the same script base. Stelara biosimilars are next, with Prolia after that. Each quarterly update on script volume and net-of-rebate pricing is a discrete catalyst that can swing the stock 4 to 8% in either direction.
Debt reduction milestones
Net debt was around $30 billion at the 2018 peak after Teva swallowed Allergan's generics arm (Actavis). At year-end 2024 the figure was around $16.5 billion. Each $1 billion reduction is treated as a step toward eventual rating upgrades. A pause or reversal would be a fast multi-percent negative reaction.
Earnings calendar and recent print history
Teva reports four times a year, almost always before the New York open. The dates cluster in the last week of January, the second week of May, the first week of August, and the first week of November. Implied moves on the option chain have generally sat between 7% and 11% going into the print.
- The market watches three lines in this order: AUSTEDO franchise revenue, total revenue versus consensus, and full-year guidance. Even a modest revenue beat can sell off if AUSTEDO disappoints.
- Cash conversion is the second screen. The opioid payment schedule is large enough that free cash flow can swing $200 to $400 million quarter on quarter purely on settlement timing. Reading the cash-flow statement alongside the income statement is mandatory.
- Conference-call tone matters. Richard Francis, the CEO since January 2023, runs a tight Pivot to Growth narrative. Any wobble on the AUSTEDO growth trajectory or the biosimilar launch curve gets pricing reaction immediately.
- Pre-announcements are rare but devastating. Teva pre-warned on 2017 guidance ahead of the dividend cut, and the stock lost a third of its value over the following six weeks. Plan for the possibility, even though it is uncommon.
When TEVA trades and which session matters
TEVA CFDs at LHFX track the NYSE-listed ADS, so the active window runs from 14:30 to 21:00 UTC, Monday through Friday. That is 09:30 to 16:00 New York time. LHFX does not route pre-market or after-hours quotes for TEVA.
Because the underlying is dual-listed, the Tel Aviv Stock Exchange tape runs Sunday through Thursday during Israeli hours. Tel Aviv frequently moves on weekend geopolitical headlines that the NYSE has not yet priced, and the Asian-session indicative levels you see in third-party data feeds often forecast where TEVA opens in New York. Traders holding TEVA over a weekend benefit from glancing at the Friday Tel Aviv close and the Sunday and Monday morning Tel Aviv prints before the US session begins.
Volume distribution within the US session is heavily skewed to the first 30 minutes and the last 30 minutes. The middle four hours of the session can be quiet enough that a 2,000-share lot moves the price by a tick or two, which matters if you are trying to scale into a multi-day position.
TEVA CFD versus direct share ownership: which fits which use case
Trading a TEVA CFD is not the same product as buying a TEVA share from a cash-equity broker, and choosing between them is a question of holding period, capital, leverage tolerance, and what you actually want to do with the position.
With a TEVA CFD you take a directional bet, you can short without locating a borrow, you only post margin (1:20 maximum at LHFX), and the contract settles in cash against the underlying NYSE ADS price. You do not vote at the annual meeting, you do not receive a paper certificate, and right now you do not collect a dividend because Teva has not paid one since 2017.
With a direct ADS purchase through a cash-equity broker you become a shareholder of record in the US transfer-agent register. You get voting rights, any future dividend, and the ability to participate in any corporate action such as a rights issue or tender offer. You pay full notional rather than margin, which means no leverage in either direction unless you separately arrange margin financing, and the position can sit untouched for years without overnight financing fees.
For a multi-day directional view on a litigation catalyst, an earnings print, or a quarterly cash-flow surprise, the CFD route is generally the cleaner instrument. For a multi-year buy-and-hold view that the AUSTEDO ramp and the debt-reduction story will eventually re-rate the stock, the direct ADS is the cleaner instrument because there is no daily swap drag.
TEVA exposure: CFD versus direct ADS versus pharma sector ETF
Three plausible ways to take a Teva-shaped position. They charge different things, behave differently in stress, and serve different holding periods.
| Attribute | TEVA CFD at LHFX | Direct TEVA ADS (cash-equity broker) | Generic-pharma sector ETF (e.g. IHF, XPH) |
|---|---|---|---|
| Exposure | Single name, 1:1 against TEVA price | Single name, 1:1 against TEVA price | Basket of 20 to 50 pharma names, TEVA is a small weight |
| Maximum leverage | 1:20 | 1:1 cash, or 1:2 with reg-T margin | 1:1 cash, or 1:2 with reg-T margin |
| Minimum capital | From $10 account deposit | Roughly one share, around $40 plus broker fees | Roughly one ETF share, around $50 to $90 |
| Cost per trade | Raw spread + $3 per side commission | Broker commission, often zero on US retail apps | Broker commission plus annual ETF expense ratio (typically 0.35 to 0.45%) |
| Short selling | Buy or sell with one click, no borrow locate | Requires locating a borrow, pays borrow fee | Possible on most ETFs but adds a borrow cost |
| Overnight cost on a long | Daily swap based on notional | None other than any opportunity cost on capital | None directly; ETF expense ratio applies |
| Voting rights and dividends | No vote, dividend adjustment passed through when paid | Full vote, full dividend when paid | ETF receives dividends and distributes them on a schedule |
| Best fit for | Defined-risk directional trades around earnings or litigation news | Multi-year buy and hold on the turnaround thesis | Diversified pharma exposure where TEVA is just one input |
If your view is specifically that AUSTEDO will or will not beat the next consensus number, the CFD is the cleanest expression. If your view is that US generic-pricing pressure has bottomed and a basket of generic makers will re-rate together, the ETF route reduces single-name litigation risk.
Trading TEVA at LHFX: the specifications and a worked example
1:20 on TEVA CFDs
$3 per side per lot, $6 round trip on 1.00 lot
MetaTrader 5 (web, desktop, mobile)
STP/ECN routing on raw spreads
$10
14:30 to 21:00 UTC, Monday through Friday
USD
Available, no separate borrow fee
Worked example: a $3,000 account taking a defined-risk long ahead of an earnings print
Suppose TEVA trades at $40.00 the day before an earnings release. You believe AUSTEDO will beat consensus and you want to take a position sized so the worst plausible single-day downside (an 11% gap, in line with the litigation-day range) costs no more than 4% of the account, which is $120.
- Maximum tolerated dollar loss: $120.
- Worst-case per-share loss in an 11% gap from $40.00: $4.40.
- Position size: $120 divided by $4.40 = 27 shares (rounded down to the nearest whole share).
- Notional value: 27 shares times $40.00 = $1,080.00.
- Margin at 1:20: $1,080.00 divided by 20 = $54.00.
- Round-trip commission: $1.62 ($3 per side per standard lot).
- If TEVA rallies 7% on the print and you exit at $42.80, gross profit on 27 shares is $75.60 less $1.62 commission, or $73.98 net (around 2.5% on the account).
- If TEVA gaps 11% lower and your stop fills at $35.60, the loss is $118.80 plus $1.62 commission, or $120.42 net (around 4% on the account, close to your planned limit).
Two practical points. First, gap fills can slip past your stop on a violent print, which is why sizing assumes the full 11% rather than the stop level. Second, the $54.00 margin is the funding requirement, not the risk; treating margin as the risk number is the single most common error in single-stock CFD trading.
What can go wrong with a TEVA position
Beyond standard equity-market risk, two TEVA-specific risk threads need to be in any trade plan.
Headline-driven litigation gaps
Opioid-related state and tribal claims, antitrust litigation over generic-drug pricing, and ongoing class actions can produce 6 to 12% single-session moves on no economic catalyst. A US attorney-general press conference, a federal court docket entry on a Friday afternoon, or an unexpected settlement-amendment headline are all live possibilities on any trading day. Stops can and do gap through their level in those moments.
Generic-pricing shock from a single procurement decision
Walmart, CVS Caremark, Express Scripts, and the major hospital group purchasing organisations each control enough script volume to move Teva's North American generic revenue by hundreds of millions of dollars when they re-bid a category. A single procurement headline can trigger a 5 to 8% reaction even outside an earnings window because analysts immediately rebuild their generic-pricing assumptions.
Currency and dual-listing dislocation
Because Teva is dual-listed in New York and Tel Aviv, an Israeli-specific macro shock, a sharp shekel move, or a war-related dislocation can produce a gap on the Tel Aviv exchange that the NYSE ADS has to absorb at the next US open. The CFD tracks the NYSE listing, so the gap arrives at 14:30 UTC for a US-session trader.
Cumulative swap drag on a long-duration position
TEVA CFDs accrue an overnight swap fee that is small per night but meaningful across multiple weeks. Holding a small long for a 90-day turnaround thesis can incur swap costs that materially erode the expected return. Calculate the cumulative cost before entry, not after.
The defensive posture is uniform across all four: keep position size such that an 11% adverse single-session move is survivable inside your defined risk per trade, set a hard stop before clicking buy, and avoid concentration when a litigation calendar window is open.